Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2013

01.09.2013 | Thoracic Oncology

Lymph Node Harvest in Esophageal Cancer After Neoadjuvant Chemoradiotherapy

verfasst von: Ravi Shridhar, MD, PhD, Sarah E. Hoffe, MD, Khaldoun Almhanna, MD, MPH, Jill M. Weber, MPH, Michael D. Chuong, MD, Richard C. Karl, MD, FACS, Kenneth Meredith, MD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

This study was designed to determine the effects of lymph node (LN) harvest on survival in esophageal cancer after neoadjuvant chemoradiation (nCRT).

Methods

An analysis of surgically resected esophageal cancer patients after nCRT was performed to determine an association between the number of LNs resected and survival. Overall survival (OS) and disease-free survival (DFS) curves were calculated according to the Kaplan–Meier method and log-rank analysis. Multivariate analysis (MVA) was performed by the Cox proportional hazard model.

Results

We identified 358 patients with a mean follow-up of 27.3 months. The number of LN removed was not impacted by the type of surgical procedure. The number of LNs removed (<10 vs. ≥10, <12 vs. ≥12, and <15 vs. ≥15) did not impact OS or DFS. We found a significant difference in OS and DFS by pathologic response. The median and 5-year OS for patients with complete, partial, and no response was 65.6 months and 52.7 %, 29.7 months and 30.4 %, and 17.7 months and 25.4 % (p = 0.0002). However, the number of LN harvested did not impact OS and DFS when patients were stratified by pathologic response. MVA also revealed that the number of lymph nodes removed was not prognostic for OS or DFS. Higher age, higher stage, and less than a complete response were associated with a decreased OS. Higher stage and less than a complete response were prognostic for worse DFS.

Conclusions

The number of LNs harvested during esophagectomy does not impact survival after nCRT. Stage and pathologic response continue to be the strongest prognostic factors for survival in esophageal cancer after nCRT.
Literatur
1.
Zurück zum Zitat Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.PubMedCrossRef Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.PubMedCrossRef
2.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.PubMedCrossRef Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.PubMedCrossRef
3.
Zurück zum Zitat Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112(6):1239–46.PubMedCrossRef Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112(6):1239–46.PubMedCrossRef
4.
Zurück zum Zitat Hsu PK, Wang BY, Chou TY, Huang CS, Wu YC, Hsu WH. The total number of resected lymph node is not a prognostic factor for recurrence in esophageal squamous cell carcinoma patients undergone transthoracic esophagectomy. J Surg Oncol. 2011;103(5):416–20.PubMedCrossRef Hsu PK, Wang BY, Chou TY, Huang CS, Wu YC, Hsu WH. The total number of resected lymph node is not a prognostic factor for recurrence in esophageal squamous cell carcinoma patients undergone transthoracic esophagectomy. J Surg Oncol. 2011;103(5):416–20.PubMedCrossRef
5.
Zurück zum Zitat Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248(4):549–56.PubMed Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248(4):549–56.PubMed
6.
Zurück zum Zitat Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.PubMedCrossRef Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.PubMedCrossRef
7.
Zurück zum Zitat Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11(11):1384–93.PubMedCrossRef Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11(11):1384–93.PubMedCrossRef
8.
Zurück zum Zitat Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17(4):1159–67.PubMedCrossRef Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17(4):1159–67.PubMedCrossRef
9.
Zurück zum Zitat Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K et al. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012;19(5):1678–84.PubMedCrossRef Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K et al. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012;19(5):1678–84.PubMedCrossRef
10.
Zurück zum Zitat Shridhar R, Dombi GW, Finkelstein SE, Meredith KL, Hoffe SE. Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the surveillance, epidemiology, and end results database. Cancer. 2011;117(17):3908–16.PubMedCrossRef Shridhar R, Dombi GW, Finkelstein SE, Meredith KL, Hoffe SE. Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the surveillance, epidemiology, and end results database. Cancer. 2011;117(17):3908–16.PubMedCrossRef
11.
Zurück zum Zitat Govindarajan A, Gönen M, Weiser MR, Shia J, Temple LK, Guillem JG, Paty PB, Nash GM. Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. J Clin Oncol. 2011;29(34):4568–73.PubMedCrossRef Govindarajan A, Gönen M, Weiser MR, Shia J, Temple LK, Guillem JG, Paty PB, Nash GM. Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. J Clin Oncol. 2011;29(34):4568–73.PubMedCrossRef
12.
Zurück zum Zitat Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124–30.PubMedCrossRef Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124–30.PubMedCrossRef
13.
Zurück zum Zitat Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedCrossRef Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedCrossRef
Metadaten
Titel
Lymph Node Harvest in Esophageal Cancer After Neoadjuvant Chemoradiotherapy
verfasst von
Ravi Shridhar, MD, PhD
Sarah E. Hoffe, MD
Khaldoun Almhanna, MD, MPH
Jill M. Weber, MPH
Michael D. Chuong, MD
Richard C. Karl, MD, FACS
Kenneth Meredith, MD, FACS
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2988-4

Weitere Artikel der Ausgabe 9/2013

Annals of Surgical Oncology 9/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.